This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mercadante, S. Articles by Girelli, D. Search for Related Content PubMed PubMed Citation Articles by Mercadante, S. Articles by Girelli, D. Pubmed/NCBI databases Medline Plus Health Information Cancer Cancer Chemotherapy Palliative Care Social Bookmarking                         What's this?

Injustifiable use of gastroprotection in advanced cancer patients

Pain Relief and Palliative Care Unit, La Maddalena Cancer Center, Palermo, terapiadeldolore{at}lamaddalenanet.it

Fabrizio David

Pain Relief and Palliative Care Unit, La Maddalena Cancer Center, Palermo

Salvatore Riina

Pain Relief and Palliative Care Unit, La Maddalena Cancer Center, Palermo

Davide Girelli

Pain Relief and Palliative Care Unit, La Maddalena Cancer Center, Palermo

The aim of this survey was to prospectively collect data about gastroprotector prescription at admission of an acute pain relief and palliative care unit. An observational survey was performed on three-hundred consecutive patients. Reasons for admission, concomitant treatment and use of drugs were recorded at admission. About 60.6% patients had been prescribed proton pump inhibitors or anti-H2 receptors agents. Of these patients, possible risk factors were nonsteroidal anti-inflammatory drugs (41, 22.5%), corticosteroids (43, 23.6%), age > 75 years (27, 14.8%). In only 25 admissions (13.7%) prescription corresponded to Italian drug agency recommendations with an odds ratio of an off-label prescription of 7.28. In a relatively high percentage of admissions (55%), patients receiving gastroprotectors were on chemotherapy, with an odds ratio of 1.42.

This survey showed that gastroprotectors are often prescribed regardless of Health Care System regulations, as only a minority of patients satisfied the requirements of an appropriate and refundable prescription. The attitudes of oncologists who prescribe gastroprotectors for a putative protective effects are not supported by evidence. Health Care Service in Italy should be aware of these problems to improve the strategies of budgeting the drug expense in a better way or providing further guidelines based on studies able to demonstrate the real cost-benefit ratio of this class of drugs. Palliative Medicine 2007; 21 : 631—633

Key Words: cancer • chemotherapy • costs • gastroprotection • gastroprotectors • NSAIDs • opioids • palliative care

Palliative Medicine, Vol. 21, No. 7, 631-633 (2007)
DOI: 10.1177/0269216307082661


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?